Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises

Clear Street, (“Clear Street”, “the Company”) a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street’s leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives products and markets.

Ed Tilly, President and CEO-Elect of Clear Street said, "The launch of our Healthcare Equity Research franchise demonstrates our commitment to providing capabilities that align with our clients' evolving needs. Our expanded equity research service complements our full suite of existing products and allows us to continue providing institutional clients the tools, teams and capabilities they need to navigate global markets and execute successful investment strategies."

Led by Director of Research Mara Goldstein, the new Healthcare Research franchise provides in-depth market analysis and investment insights to the firm’s expanding institutional client base. To launch coverage, Clear Street has appointed Kaveri Pohlman, Ph.D. and William “Bill” Maughan, Ph.D. as Managing Directors and Senior Equity Analysts, reporting to Ms. Goldstein.

“Fueled by scientific advancements across all fields of medicine, the healthcare sector, particularly biotechnology, has grown immensely and has become a fundamentally important sector of the economy for investors,” said Ms. Goldstein. “As the number of biotechnology companies continues to grow, we think it’s important to be a voice in the space, analyzing and highlighting under-followed and under-represented companies that our clients, such as specialist hedge funds and dedicated healthcare fund investors care about.”

Dr. Kaveri Pohlman’s research coverage will initially focus on oncology and autoimmune disease (I&I), spanning multiple technologies, from cell to gene therapy. Prior to joining Clear Street, Dr. Pohlman was a Senior Analyst at BTIG where she covered large and small-cap biotechnology companies. Dr. Pohlman earned a Ph.D. in molecular and cellular biology from SUNY Downstate Medical Center, an MS in biotechnology from New York University’s Tandon School of Engineering and an MBA from Birla Institute of Management Technology.

Dr. Bill Maughan brings deep experience in Equity Research across several therapeutic areas, and will continue to do so at Clear Street, including oncology, ophthalmology and genetic medicine, including RNA technologies. Prior to joining Clear Street, Dr. Maughan was a Senior Biotechnology Analyst with Canaccord Genuity, focusing on solid tumor oncology. Dr. Maughan earned a Ph.D. in Biochemistry, Cell and Molecular Biology at the Weill Cornell Graduate School of Medical Sciences and a bachelor’s degree in Biological Sciences from Fordham University.

Specific coverage launch includes:

Healthcare: Biotechnology

• Cargo Therapeutics (Nasdaq: CRGX)
• Century Therapeutics (Nasdaq: IPSC)
• Cullinan Therapeutics (Nasdaq: CGEM)
• Delcath Systems (Nasdaq: DCTH)
• Enliven Therapeutics (Nasdaq: ELVN)
• Erasca (Nasdaq: ERAS)
• Immatics (Nasdaq: IMTX)
• Janux Therapeutics (Nasdaq: JANX)
• MoonLake Immunotherapeutics (Nasdaq: MLTX)
• Nuvation Bio (NYSE: NUVB)
• Protagonist Therapeutics (Nasdaq: PTGX)
• YmAbs Therapeutics (Nasdaq: YMAB)

The launch of Healthcare Equity Research enhances Clear Street’s growing research franchise and complements the Company’s already existing product offerings across prime brokerage, professional clearing, futures trading and investment banking services. The expanding Equity Research offering demonstrates Clear Street’s commitment to areas where institutional clients are actively seeking specialized insights. The Company also recently launched Clear Street UK, a pivotal step in building a global, full-service institutional business powered by cloud-based, financial technology.

About Clear Street:

Clear Street is modernizing the brokerage ecosystem with financial technology and services that empower market participants with real-time data and best-in-class products, tools and teams, to navigate capital markets around the world. Complemented by white-glove service, Clear Street's cloud-native, proprietary product suite delivers financing, derivatives, execution and more to power client success, adding efficiency to the market and enabling clients to minimize risk, redundancy and cost. Clear Street’s goal is to create a single platform for every asset class, in every country and in any currency. For more information, visit https://clearstreet.io.

Clear Street does not provide investment, legal, regulatory, tax, or compliance advice. Consult professionals in these fields to address your specific circumstances. These materials are: (i) solely an overview of Clear Street’s products and services; (ii) provided for informational purposes only; and (iii) subject to change without notice or obligation to replace any information contained therein.

Products and services are offered by Clear Street LLC as a Broker Dealer member FINRA and SIPC and a Futures Commission Merchant registered with the CFTC and member of NFA. Additional information about Clear Street is available on FINRA BrokerCheck, including its Customer Relationship Summary and NFA BASIC | NFA (futures.org).

Copyright © 2024 Clear Street LLC. All rights reserved. Clear Street and the Shield Logo are Registered Trademarks of Clear Street LLC

View source version on businesswire.com: https://www.businesswire.com/news/home/20241217931998/en/